{"schema_version":"1.0","type":"article","title":"新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.md","lang":"zh-Hant","date":"2026-09-02","publish_at":"2026-09-02T08:00:00+08:00","updated_at":"2026-09-02","category":"商業分析系列","topic":"商業分析系列","tags":["Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","生技商業化","現金流","新藥上市"],"summary":"ORLYNVAH 上市第一季只有 40 萬美元淨產品收入，同季銷售、一般與管理費約 650 萬美元；約七個月後，Iterum 聲請清盤。Karyopharm 與 Theravance 的情況不同，卻共同顯示新藥核准後，收入、成本、管線與資本四座時鐘會同時啟動。","key_points":[],"facts":[],"sections":["01｜Iterum：40 萬美元收入，撞上 650 萬美元費用","02｜Karyopharm：第一名的靶點，救不了最後一名的現金表","03｜Theravance：不是撐不下去，而是不想再拿現金賭下一次","04｜真正的商業化能力，不是把藥賣出去","05｜看商業化 Biotech，先看四個時鐘","06｜給台灣與中國生技公司的真正警告","結語｜FDA 給的是門票，不是續命丹"],"references":[],"images":[{"alt":"圖 1｜新藥上市不是終點：收入、成本、管線與資本四個時鐘同時啟動","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/cover.png"},{"alt":"圖 2｜Iterum 七個月商業化倒數：40 萬美元收入對上 650 萬美元費用","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-02.png"},{"alt":"圖 3｜Karyopharm 壓力測試：產品收入、現金、債務與新適應症同時倒數","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-03.png"},{"alt":"圖 4｜三種結局：Iterum 清算、Karyopharm 壓力測試、Theravance 價值退出","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-02）。新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後。https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-02-post-approval-biotech-commercialization-death-valley-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}